Kardiologiia · 2005
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ol'binskaia L I, Kolosova K Iu, Nesterova S G, Egorova T D, Fedorova A Iu
Аннотация
Modern approaches to prevention of venous thromboembolic complications in patients with chronic heart failure are analyzed in this review which contains results of large studies of low molecular weight heparins. In MEDENOX trial the use of enoxaparin in medical patients was associated with 63% reduction of risk of thrombosis. The authors own experience showed that 2 weeks of therapy with enoxaparin in patients with chronic stage IIB-III heart failure caused significant lowering of soluble fibrin-monomer complexes, fibrinogen, and index of turbo-dynamic potential. These changes evidenced for decreased intravascular blood coagulation. Thus enoxaparin can be effectively used for prevention of thrombosis and thromboembolism in patients with chronic heart failure. Novel antithrombotic agents fondaparinux, idraparinux, ximelagatran, recombinant thrombomodulin are perspective medications for prevention of venous thromboses and embolism in medical patients.
Предметные рубрики MeSH
AnticoagulantsAzetidinesBenzylaminesDalteparinDouble-Blind MethodEnoxaparinFibrinolytic AgentsFondaparinuxHeart FailureHumansMulticenter Studies as TopicOligosaccharidesPlacebosPolysaccharidesRandomized Controlled Trials as TopicRisk FactorsThromboembolismThrombomodulinThrombosisTime FactorsVenous Thrombosis